Navigation Links
Bionovo to Present at the Cambria Capital Investor Meeting
Date:3/26/2008

EMERYVILLE, Calif., March 26 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI), a leader in the discovery and development of safe and effective drugs in the areas of women's health and cancer, is scheduled to present at the Cambria Capital Investor Meeting in Salt Lake City on March 27, 2008 at 4:00 p.m. MDT.

Isaac Cohen, O.M.D., Chairman and CEO, and Mary Tagliaferri, M.D., President and CMO are both scheduled to present, along with Tom Chesterman, SVP and CFO. The purpose of the presentation will be to update investors on the current business developments and goals for 2008.

No webcast or archive will be available for this presentation. Those investors wishing to attend should contact Cambria Capital at (877) 224-0477 toll free, (801) 320-9606 main or by email at clientservices@cambriacapital.com.

About Cambria Capital, LLC

Cambria Capital, LLC ("Cambria") is an investment banking and securities brokerage firm with offices in Salt Lake City, Los Angeles and San Francisco. Cambria's mission is to facilitate the growth and development of promising companies at all stages of development by providing capital and a wide variety of financial advisory services. The financing arranged by Cambria originates from a number of sources, including the firm's principals and Cambria's network of high net-worth individuals and institutional investors. Cambria employs a number of corporate finance structures, including PIPEs (Private Investments in Public Equities), private placements of equity and debt securities and reverse mergers. Cambria is a member of the Financial Industry Regulatory Authority, Inc. ("FINRA"), and the Securities Investor Protection Corporation (SIPC). Visit the Cambria website at http://www.cambriacapital.com

About Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bionovo Announces Closing of Public Offering of Common Stock
2. Bionovo Describes a New Class of Therapeutic Compounds
3. Bionovo Announces 2007 Financial Results and Highlights
4. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
5. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
6. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
7. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
8. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
9. AtriCure to Present at Roth Capital Partners 2007 New York Conference
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. MDS to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... ... pharmacies, will be represented at the 2016 Asembia Specialty Pharmacy Summit held May ... is the largest U.S. health care conference for the specialty pharmacy industry, with ...
(Date:5/3/2016)... ... 2016 , ... University of the People, the world’s first ... Associates and Bachelor's degrees in Health Studies. Leading figures are heading the program’s ... Wiesel; Chairman and CEO of Fortune 500® company Henry Schein, Stanley M. Bergman; ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... that it is launching a new client service center in La Vergne, Tennessee, ... and will provide the full range of Empyrean client services. , “Our Nashville-area ...
(Date:5/3/2016)... ... May 03, 2016 , ... Nationally recognized personal injury law firm Monge & ... giving free roses to anyone who wants one for their Mother or any other mother ... important valuable contributions of Mothers.” Monge goes on to say, “we are choosing to ...
(Date:5/3/2016)... ... 2016 , ... Park Cities Pet Sitter has openings for both full-time and ... 75206, 75209, 75219, 75220, 75225, 75229, 75230, 75231 and 75235 zip codes. These ... Preston Hollow and Park Cities areas of the Metroplex. Candidates must love animals, ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
(Date:4/29/2016)... 2016 Automation is one of ... to the growing demands for productivity in speed, accuracy, ... systems are already adept of a wide range of ... manual labor. Instrumentation continues to evolve, and is poised ... a few years ago. Originally used mostly by the ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s ... complement the company,s valve repair and stent business, ... also places Abbott more firmly into patient monitoring.  ... the fastest growing device areas, with double-digit growth ... recent report,  Advanced Remote Patient Monitoring ...
Breaking Medicine Technology: